TRIPLE-S MANAGEMENT CORPORATION: Selects Abarca as Pharmacy Benefits Manager for its Commercial and Medicare Businesses

Triple-S Management Corporation (NYSE: GTS), announced that its managed care subsidiary, Triple-S Salud, Inc., on its behalf and on behalf of its Medicare Advantage subsidiary, Triple-S Advantage, Inc. ("Triple-S" or the "Company"), has entered into a three-year agreement with Abarca Health, LLC, a leading pharmacy benefits manager (PBM) in Puerto Rico, to consolidate the management of its prescription drug benefit programs for its Commercial and Medicare business lines. Read More »

REGENERON PHARMACEUTICALS, INC.: FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) of EYLEA® (aflibercept) Injection for the treatment of diabetic retinopathy (DR), the leading cause of vision loss for patients with diabetes. Read More »